You don’t have permission to view the content
University of Birmingham Panel Session
My name is Alice and I am a Research Scientist at Future Genetics.
In keeping with the ethos of empowerment at Future Genetics, Dr Mohammed Kamran, who is the CEO and Medical Director of the organisation, will be participating in a panel discussion being held at the University of Birmingham, titled ‘Insights into Science: in and out of Labs’. The event is being held on Wednesday the 30th of January.
This provides an opportunity for students at the University of Birmingham to gain insights into the career opportunities that are available to them and capture the experiences and perspectives of the panel speakers. The speaker panel consists of 6 members, that include 2 patent attorney and trademark specialists, an application team manager, a business engagement manager, a life sciences recruitment consultant, as well as Dr Kamran, who will provide insights into his academic, clinical trials and research and development experiences.
This event compliments another event that Dr Kamran spoke at, which was the Aston University Careers Event in December 2018. For those who are interested, please click the link below.
Given our relationship with the University of Birmingham, we hope Future Genetics can add value to the next generation of Scientists, Entrepreneurs and Innovators.
Mental illnesses are continuously affecting individuals and families. There are a wide range of mental illnesses that fall into different sub categories. Examples of mental illnesses include Depression, anxiety, Bipolar and Schizophrenia.
25% of young women suffer from a mental illness
Everyday more and more people are diagnosed with a mental illness especially women. Mental illnesses are also becoming more frequent in the younger population. A recent study conducted in 2017 by the NHS and involved more than 9,000 individuals. The results of this study were that 1 in 4 Young women will develop a mental illness and a total of 23.9% reported having a disorder.
More needs to be done around the topic of mental illnesses due to how common they are amongst the whole population. Mental illnesses are most common in young females. I believe that more needs to be done around the topic of mental illnesses due to how common they are amongst the whole population. As they are most common in young females I hope I will be able to help other young females who are suffering from a mental illness by contributing to creating awareness around this issue.
Poor Mental Health and triggers
There are many factors which may contribute to the development of a mental Illness in young females such as exam stress, which a large proportion of teenagers will have to face. Body image is also a significant factor. This factor is enhanced by social media which constantly promotes an idealistic image, in addition social media also causes a constant comparison against other girls. However, it is debatable whether or not social media can be solely blamed despite being a factor. Social media is extremely time consuming with nearly one third of children spending at least four hours on these apps. Those who did have a mental health problem were two to three times less likely to spend at least 4 hours on social media which shows it does have a negative impact. The ways it appears to have negative impact is by the number of likes, comparison and cyber-bullying as well. Despite this social media cannot be blamed as the only culprit. As sometimes social media can be used to support an individual who is suffering from a mental illness.
Affected populations & support frameworks
These factors are not only specific to females but males as well, especially the younger population, as 1 in 9 children aged between 5-15 are reported to have a disorder. This figure has been rising over the years as it now stands at 11.2% in comparison to 9.7% in 1999. Figures are constantly rising but not all young people are receiving the help and support they need. This is shown by how nearly a third of young individuals who were referred to community services got turned away. Even those who received help had to wait an alarming average time period of 2 months. 32% were waiting for treatment at the end of the year and 15% had to wait over 6 weeks to even be seen. This needs to change, young, at risk and vulnerable children should not have to wait these time periods to receive treatment or to be seen.
Arthritis is an illness which affects numerous people and it results in the inflammation of the joints. It can affect one or multiple joints. There are several different forms of arthritis. Approximately 350 million people have Arthritis worldwide, with a total of 10 million of these people are living in the United Kingdom. This illness is treated by the use of a number of different drugs including a drug called Adalimumab. A protein called tumour necrosis factor (TNF) is produced by the immune system naturally. However, in arthritis, the inflammation is caused by a protein called tumour necrosis factor (TNF) being overproduced.
Adalimumab is a monoclonal antibody that acts as a TNF blocker. It it works by binding to the TNF molecules. The action of binding then prevents the molecules of TNF attaching to the body’s healthy cells. This then reduces inflammation of the joints.
My name is Lucy Field and I am a research Scientist at Future Genetics. I have just read an article that focuses on the development of a new drug which treats Arthritis.
The new drug is a biosimilar version of Adalimumab. The development of this new drug has a positives impact on the NHS and their budget. The reasoning for this is because Adalimumab was a medicine that Hospitals spend nearly £400 million a year on making it a relatively expensive medicine. The new biosimilar version will only cost a quarter of this amount allowing the NHS to save up to £300 million a year by 2021. This outstanding cut from the national annual medicines bill is the biggest NHS saving from a single drug negotiation.
NHS Cost Savings
The money from this saving could be used to employ 11,700 more community nurses or 19,800 more breast cancer treatments for patients which could potentially save the lives of thousands of women. This highlights the importance of biosimilar drugs and how a smarter approach to biosimilar drugs across Europe gives patients and taxpayers a better deal.
The saving is due to negotiations with 5 new drug companies who will manufacture bio-similar versions of the dug. These companies are Amgen, Biogen, Mylan/Fujifilm Kyowa Kirin, Sandoz, and AbbVie. This comes after the exclusive patent for Adalimumab (Humira) expired. From December onwards, the new biosimilar versions of the drug from these new companies should be available.
According to the NHS 9 out of 10 new patients should be started on the best value medicine 3 months after the launch of the biosimilar medicine.
Future Genetics will be at the Lab Innovations Conference, 2018
Future Genetics is committed to high quality and innovative genomics research.
Our Research Scientist, Lucy Field, will be attending the Lab Innovations 2018 Conference at the NEC this week (31 Oct). She looks forward to meeting you all and learning from all the exciting exhibitions which will be showcased.
Future Genetics will be looking for new and innovative technologies that can help us accelerate our research in genomics, medicine and patient healthcare.
Looking forward to the conference